Skip to content

Study · In vitro (cells) · 1994

1 result

Effect of a new, potent, non-peptide V1a vasopressin antagonist, SR 49059, on the binding and the mitogenic activity of vasopressin on Swiss 3T3 cells.

Serradeil-Le Gal C, Bourrié B, Raufaste D, Carayon P, Garcia C, Maffrand JP, Le Fur G, Casellas P

Biochemical pharmacology1 Feb 1994Cited by 19 (Europe PMC)

PMID8129742 (opens in a new tab)DOI10.1016/0006-2952(94)90125-2 (opens in a new tab)PepBankPUB-08129742
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In Swiss 3T3 cell membranes, oxytocin showed low affinity for the AVP V1a receptor site (IC50 above 1 microM).

    In plain wordsIn cell tests, oxytocin bound only weakly to the vasopressin V1a receptor site on Swiss 3T3 cells.

    Peptide
    Oxytocin
    Outcome
    Not applicableOxytocin affinity at AVP V1a receptors of Swiss 3T3 cells
    Study

    n: not reported in source

    Swiss 3T3 cell membranes, 125I-linear AVP antagonist binding
    Comparator
    DDAVP (V2 agonist), also low affinity
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated · in vitro (binding assay)As given in this study.

    Measurements

    IC50
    > 1 microM
    Swiss 3T3 cell membranes

    Source sentences

    Summary
    Both DDAVP, a selective V2 agonist, and oxytocin exhibited low affinity (IC50 > 1 microM) in agreement with the AVP V1a nature of the site identified on Swiss 3T3 cells.
    1 context sentence
    Summary · context
    We characterized the AVP V1a receptors on Swiss 3T3 cell membranes using the new highly specific AVP V1a radioiodinated ligand, 125I-linear AVP antagonist.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 20:03 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:54 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.